Chronic beryllium disease in a precious metal refinery. Clinical epidemiologic and immunologic evidence for continuing risk from exposure to low level beryllium fume.
The occurrence of chronic beryllium (7440417) disease in a precious metal refinery was investigated. Five workers at a facility that refined and reclaimed gold and silver from industrial scrap (SIC- 3341) developed granulomatous lung disease between 1972 and 1985. The patients were males, four Hispanics and one black, aged 31 to 41 years. The original diagnosis was sarcoidosis. Immunologic studies were performed on the four Hispanic patients utilizing in-vitro proliferative responses of lymphocytes obtained by bronchoalveolar lavage. Hypersensitivity to beryllium salts was found. The entire work force at the facility was surveyed by questionnaire and by review of prior X-rays and spirometry results for evidence of granulomatous lung disease. No current workers had radiographic or spirometric evidence suggestive of chronic beryllium disease. Industrial hygiene air monitoring of the facility showed beryllium concentrations of 0.22 to 42.3 micrograms per cubic meter (microg/m3), mean 1.2microg/m3. Ten percent of the samples were in excess of the current permissible exposure limit of 2.0microg/m3. Moderate concentrations of other metal contaminants, such as arsenic (7440382), lead (7439921), and cadmium (7440439), were also found. The authors conclude that chronic beryllium disease mimicking sarcoidosis still occurs from modern industrial exposures. A significant risk for chronic beryllium disease exists among approximately 30000 to 800000 American workers exposed to beryllium, especially those, workers, who smelt, burn, refine, or weld the metal or its alloys, possibly even if exposure concentrations are below presently adopted standards.
Links with this icon indicate that you are leaving the CDC website.
The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
You will be subject to the destination website's privacy policy when you follow the link.
CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website.
For more information on CDC's web notification policies, see Website Disclaimers.
CDC.gov Privacy Settings
We take your privacy seriously. You can review and change the way we collect information below.
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.
Cookies used to make website functionality more relevant to you. These cookies perform functions like remembering presentation options or choices and, in some cases, delivery of web content that based on self-identified area of interests.
Cookies used to track the effectiveness of CDC public health campaigns through clickthrough data.
Cookies used to enable you to share pages and content that you find interesting on CDC.gov through third party social networking and other websites. These cookies may also be used for advertising purposes by these third parties.
Thank you for taking the time to confirm your preferences. If you need to go back and make any changes, you can always do so by going to our Privacy Policy page.